Real-world administration blinatumomab in the outpatient setting: Toxicity outcomes and healthcare utilizationYannis K. Valtis, Evan C. Chen, Benjamin Frost et al.|Blood|2025Cited by 0
Prognosis in adults with ph-positive B-ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease (≥10-4) pre-blinatumomabBenjamin Frost, Evan C. Chen, David Nemirovsky et al.|Blood|2025Cited by 0